Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir

Model NO.
D-sung-Ganciclovir
Shelf Life
2 Years
CAS No
82410-32-0
Test Method
HPLC, UV
Specific
COA
Density
1.81
Boiling Point
Boiling Point
MW
255.23062
Mf
C9h13n5o4
Grade
Pharmaceutical Grade
Color
White Color
Application
Pharmaceutical
Assay
HPLC 99%
Name
Ganciclovir Powder
Appearance
White Powder
Product Name
Ganciclovir
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
5000kg/Month
Reference Price
$ 135.00 - 198.00
Contact Us

Product Description

Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir
Pharmaceutical Ganciclovir powder Raw Material Ganciclovir Powder Ganciclovir
Product Description
Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir
Product Details
Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir
Product name Ganciclovir
Cas number 82410-32-0
Appearance White powder
MF C9H13N5O4
MW 255.23062
Ganciclovir is commonly associated with a range of serious haematological adverse effects. Common adverse drug reactions (≥1% of patients) include: granulocytopenia, neutropenia, anaemia, thrombocytopenia, fever, nausea, vomiting, dyspepsia, diarrhea, abdominal pain, flatulence, anorexia, raised liver enzymes, headache, confusion, hallucination, seizures, pain and phlebitis at injection site (due to high pH), sweating, rash, itch, increased serum creatinine and blood urea concentrations.
Application&Function
Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir 1. Induction and maintenance treatment of CMV retinitis in immunocompromised patients (including AIDS patients).
2. Prevention of cytomegalovirus infection in patients receiving organ transplants and prophylaxis of cytomegalovirus disease in HIV-positive patients with cytomegalovirus seroprevalence.
For immunodeficient patients with life-threatening or vision-related cytomegalovirus (CMV) infections, such as AIDS, exogenous immunosuppressive patients associated with organ transplantation and tumor chemotherapy.
Antiviral drugs, for the treatment of cytomegalovirus (CMV) infections caused by low immune capability.
For antiviral drugs intermediates.
Specification
Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir
Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir Pharmaceutical Ganciclovir Powder Raw Material Ganciclovir Powder Ganciclovir

 

 

Pharmaceutical Intermediate

PNEUTEC.IT, 2023